<DOC>
	<DOC>NCT01607294</DOC>
	<brief_summary>This Phase 2 study will asses the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes.</brief_summary>
	<brief_title>A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Diagnosis of type 2 diabetes meeting all of the following: Minimum 6 month history of diabetes prior to screening visit; Fasting Cpeptide ≥ 0.8 ng/mL at screening visit; HbA1C at screening visit 710%; Fasting glucose from 140270 mg/dL on Day 7 following washout of all glucose regulating drugs and supplements. BMI at screening visit from 2535 kg/m2; LDLC at screening ≥ 100 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>